๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

โœ Scribed by Gane, Edward J.; Stedman, Catherine A.; Hyland, Robert H.; Ding, Xiao; Svarovskaia, Evguenia; Symonds, William T.; Hindes, Robert G.; Berrey, M. Michelle

Book ID
120182712
Publisher
Massachusetts Medical Society
Year
2013
Tongue
English
Weight
594 KB
Volume
368
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Nucleotide Polymerase Inhibitor Sofosbuv
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
โœ Gane, Edward J.; Stedman, Catherine A.; Hyland, Robert H.; Ding, Xiao; Svarovska ๐Ÿ“‚ Article ๐Ÿ“… 2013 ๐Ÿ› Massachusetts Medical Society ๐ŸŒ English โš– 594 KB

## BACKGROUND The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated so fos bu vir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for th

The protease inhibitor, GS-9256, and non
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
โœ Stefan Zeuzem; Peter Buggisch; Kosh Agarwal; Patrick Marcellin; Daniel Sereni; H ๐Ÿ“‚ Article ๐Ÿ“… 2012 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 897 KB

Tegobuvir (GS-9190), a non-nucleoside nonstructural protein (NS)5B polymerase inhibitor, and GS-9256, an NS3 serine protease inhibitor, individually have activity against hepatitis C virus (HCV) genotype 1. The antiviral activity of tegobuvir and GS-9256 as oral combination therapy, or together with